Literature DB >> 24533823

DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo.

Peng Zhang1, Bei-Bei Zheng, Hong-Yuan Wang, Jin-Hua Chen, Xin-Yong Liu, Xiu-Li Guo.   

Abstract

OBJECTIVES: We investigated the chemo-sensitization of a ligustrazine derivate, (E)-2-(2, 4-dimethoxystyryl)-3, 5, 6-trimethylpyrazine (DLJ14) on Adriamycin (Adr, Wanle, Shenzhen, China)-resistant human breast cancer (MCF-7/A) cells both in vivo and in vitro.
METHODS: The antitumour effects of DLJ14 and Adr was observed in MCF-7/A cells by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in vitro and was evaluated by MCF-7/A xenografts in nude mice. The intracellular Adr accumulation was assessed by mean fluorescence intensity of Adr. The messenger RNA level of glutathione (GSH) S-transferase (GST)π in MCF-7/A cells was determined by real-time reverse transcription PCR assay. The expression of GSTπ, c-jun NH2 -terminal kinase (JNK) and phosphor-JNK (p-JNK) was detected by Western blotting method. KEY
FINDINGS: The MTT results showed that DLJ14 exhibited a weak inhibition on proliferation of both MCF-7 and MCF-7/A cells, in contrast with the strong inhibition of verapamil. When DLJ14 is combined with Adr, the inhibitory effect on MCF-7/A cells and MCF-7/A xenografts was enhanced significantly through increasing intracellular accumulation of Adr by inhibition of GSH level and the activity of GSH peroxidase and GST. Moreover, DLJ14 could downregulate the expression of GSTπ and increase the expression of JNK and p-JNK in MCF-7/A cells or in xenografts.
CONCLUSION: DLJ14 is a promising chemo-sensitization candidate for the reversal of multidrug resistance in cancers.
© 2013 Royal Pharmaceutical Society.

Entities:  

Keywords:  (E)-2-(2,4-dimethoxystyryl)-3,5,6-trimethylpyrazine (DLJ14); Adr-resistant human breast cancer cell (MCF-7/A cell); glutathione S-transferase π (GSTπ); multiple drug resistance; tumour xenograft

Mesh:

Substances:

Year:  2013        PMID: 24533823     DOI: 10.1111/jphp.12168

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3.

Authors:  Jianliang Shen; Linwen Zeng; Liangming Pan; Shaofeng Yuan; Ming Wu; Xiongdong Kong
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

Review 2.  Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms.

Authors:  Shaojie Yang; Shuodong Wu; Wanlin Dai; Liwei Pang; Yaofeng Xie; Tengqi Ren; Xiaolin Zhang; Shiyuan Bi; Yuting Zheng; Jingnan Wang; Yang Sun; Zhuyuan Zheng; Jing Kong
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

Review 3.  GSTP1 as a novel target in radiation induced lung injury.

Authors:  Xiao Lei; Lehui Du; Wei Yu; Yao Wang; Na Ma; Baolin Qu
Journal:  J Transl Med       Date:  2021-07-08       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.